<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02055521</url>
  </required_header>
  <id_info>
    <org_study_id>2013.815</org_study_id>
    <nct_id>NCT02055521</nct_id>
  </id_info>
  <brief_title>Search Tolerance Signature in Vascularised Composite Allograft</brief_title>
  <acronym>BIOCTA</acronym>
  <official_title>Search Tolerance Signature in Vascularised Composite Allograft</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ISTITUTO ITALIANO CHIRURGIA DELLA MANO, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>medizinische universität innsbruck, Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clínico Universitario de Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Composite tissue allotransplants (CTA) involve transplantation of various tissues including&#xD;
      vessels, nerves, skin, bones, and immune cells and entail a significant antigenic load. The&#xD;
      large majority of recipients have been maintained on immunosuppression therapy similar to&#xD;
      that used in solid organ transplantation that is associated with the complications usually&#xD;
      reported in solid organ transplantation. The question whether risks associated with&#xD;
      indefinite immunosuppressive are justified for a non-lifesaving procedure still remains&#xD;
      unanswered. At present no CTA recipient proved to be spontaneously tolerant with any&#xD;
      immunosuppressive protocol; indeed, until now all recipients who discontinued the&#xD;
      immunosuppressive therapy rejected their graft. On the other hand CTA recipients showed a low&#xD;
      incidence of chronic rejection despite the high incidence of acute rejection episodes.&#xD;
&#xD;
      For all these reasons it should be of great interest to minimize the immunosuppression in CTA&#xD;
      patients knowing their immunologic &quot;risk&quot;. The main outcome of this study is to search for&#xD;
      the signature of tolerance in recipients of hand or face allotransplantation testing&#xD;
      biomarkers previously identified in operational tolerant kidney transplant recipients.&#xD;
&#xD;
      These markers have been developed studying tolerant kidney recipients and they were already&#xD;
      tested in five bilateral hand transplantations and one face transplantation.&#xD;
&#xD;
      The present study will include hand and face allograft recipients transplanted at least one&#xD;
      year in several European institutions (Innsbruck, Lyon, Monza, Valencia): 11 bilateral hand&#xD;
      transplantations, 4 single hand transplantations and 3 face transplantations. All the&#xD;
      patients will undergo B cell phenotyping, TCR repertoire, molecular signature from&#xD;
      operational tolerance and a skin biopsy with immunohistochemical staining of the specimens in&#xD;
      order to show signs of acute or chronic rejection.&#xD;
&#xD;
      The results could provide a valid tool to detect operationally tolerant recipients as well as&#xD;
      recipients prone to develop chronic rejection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers of molecular signature from operational tolerance and/or chronic rejection research</measure>
    <time_frame>1 day</time_frame>
    <description>B cell phenotyping, TCR repertoire, molecular signature from operational tolerance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological characteristics of skin acute/chronic rejection on skin biopsy</measure>
    <time_frame>1 day</time_frame>
    <description>skin biopsy with immunohistochemical staining of the specimens in order to show signs of acute or chronic rejection. We will try to correlate the signature of tolerance with the absence of chronic rejection symptoms, both clinically and in skin protocol biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotype of skin T lymphocyte in cutaneous biopsies</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Hand and Face Allotransplantation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample, biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with Hand (unilateral/bilateral) or face allotransplantation for at least one&#xD;
             year&#xD;
&#xD;
          -  Patient without clinical sign of acute rejection at inclusion&#xD;
&#xD;
          -  Patient who signed the informed protocol consent&#xD;
&#xD;
          -  Patient older than 18 years old&#xD;
&#xD;
          -  Patient covered by an health insurance&#xD;
&#xD;
          -  Patient without legal protection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with Hand or face allotransplantation for less than one year&#xD;
&#xD;
          -  Patient with clinical sign of acute rejection at inclusion&#xD;
&#xD;
          -  Unsigned protocol consent&#xD;
&#xD;
          -  Patient under the age of 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>January 17, 2014</study_first_submitted>
  <study_first_submitted_qc>February 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2014</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Composite tissue allograft</keyword>
  <keyword>operational tolerance</keyword>
  <keyword>skin rejection</keyword>
  <keyword>Hand and Face allotransplantation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

